Can Total Current Liabilities vs Property Plant Equipment Analysis
CANF Stock | USD 1.96 0.01 0.51% |
Can Fite financial indicator trend analysis is way more than just evaluating Can Fite Biopharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Can Fite Biopharma is a good investment. Please check the relationship between Can Fite Total Current Liabilities and its Property Plant Equipment accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Total Current Liabilities vs Property Plant Equipment
Total Current Liabilities vs Property Plant Equipment Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Can Fite Biopharma Total Current Liabilities account and Property Plant Equipment. At this time, the significance of the direction appears to have very week relationship.
The correlation between Can Fite's Total Current Liabilities and Property Plant Equipment is 0.21. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Property Plant Equipment in the same time period over historical financial statements of Can Fite Biopharma, assuming nothing else is changed. The correlation between historical values of Can Fite's Total Current Liabilities and Property Plant Equipment is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Can Fite Biopharma are associated (or correlated) with its Property Plant Equipment. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant Equipment has no effect on the direction of Total Current Liabilities i.e., Can Fite's Total Current Liabilities and Property Plant Equipment go up and down completely randomly.
Correlation Coefficient | 0.21 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Total Current Liabilities
Total Current Liabilities is an item on Can Fite balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Can Fite Biopharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Property Plant Equipment
Most indicators from Can Fite's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Can Fite Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Can Fite's Sales General And Administrative To Revenue is most likely to decrease significantly in the upcoming years.
Can Fite fundamental ratios Correlations
Click cells to compare fundamentals
Can Fite Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Can Fite fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 286.4K | 358.4M | 553.1M | 815.7M | 1.3B | 1.3B | |
Total Assets | 8.2M | 9.5M | 20.3M | 9.3M | 10.0M | 10.5M | |
Other Current Liab | 610K | 288K | 852K | 727K | 944K | 891.4K | |
Total Current Liabilities | 3.3M | 1.3M | 2.7M | 2.5M | 2.0M | 2.4M | |
Total Stockholder Equity | 2.4M | 6.1M | 14.4M | 4.5M | 6.2M | 5.6M | |
Other Liab | 2.4M | 2.2M | 3.1M | 2.3M | 2.6M | 2.0M | |
Property Plant And Equipment Net | 118K | 123K | 185K | 126K | 81K | 87.2K | |
Net Debt | (2.6M) | (8.2M) | (4.3M) | (2.9M) | (4.2M) | (4.4M) | |
Retained Earnings | (110.3M) | (125.5M) | (140.7M) | (150.8M) | (158.5M) | (166.4M) | |
Accounts Payable | 2.2M | 561K | 954K | 896K | 427K | 833.0K | |
Cash | 2.7M | 8.3M | 4.4M | 3.0M | 4.3M | 4.6M | |
Non Current Assets Total | 1.0M | 123K | 185K | 126K | 81K | 77.0K | |
Cash And Short Term Investments | 2.8M | 8.3M | 19.1M | 8.0M | 8.9M | 8.4M | |
Net Receivables | 651K | 18K | 48K | 47K | 78K | 74.1K | |
Common Stock Total Equity | 2.4M | 2.6M | 8.2M | 33.0M | 38.0M | 39.9M | |
Liabilities And Stockholders Equity | 8.2M | 9.5M | 20.3M | 9.3M | 10.0M | 10.5M | |
Non Current Liabilities Total | 2.5M | 2.2M | 3.1M | 2.3M | 1.7M | 2.4M | |
Other Current Assets | 3.7M | 1.0M | 881K | 1.1M | 986K | 1.6M | |
Other Stockholder Equity | 103.4M | 97.4M | 93.3M | 154.2M | 163.6M | 106.5M | |
Total Liab | 5.7M | 3.4M | 5.9M | 4.8M | 3.7M | 4.8M | |
Property Plant And Equipment Gross | 119K | 123K | 185K | 126K | 344K | 361.2K | |
Total Current Assets | 7.1M | 9.4M | 20.1M | 9.2M | 9.9M | 10.3M | |
Common Stock | 2.6M | 8.2M | 33.0M | 60.7M | 69.8M | 73.2M | |
Property Plant Equipment | 118K | 123K | 185K | 126K | 144.9K | 84.8K | |
Net Tangible Assets | 2.4M | 6.1M | 14.4M | 4.5M | 4.0M | 7.2M | |
Non Currrent Assets Other | 912K | (123K) | (185K) | (126K) | (113.4K) | (107.7K) | |
Current Deferred Revenue | 469K | 334K | 818K | 783K | 622K | 594.8K | |
Net Invested Capital | 877K | 6.1M | 14.4M | 4.5M | 6.2M | 6.0M | |
Net Working Capital | 3.9M | 8.1M | 17.3M | 6.7M | 7.9M | 8.4M | |
Short Term Investments | 64K | 75K | 14.7M | 5.0M | 4.6M | 4.5M |
Currently Active Assets on Macroaxis
When determining whether Can Fite Biopharma is a strong investment it is important to analyze Can Fite's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Can Fite's future performance. For an informed investment choice regarding Can Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Can Fite. If investors know Can will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Can Fite listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.60) | Quarterly Revenue Growth (0.19) | Return On Assets (0.57) | Return On Equity (1.58) |
The market value of Can Fite Biopharma is measured differently than its book value, which is the value of Can that is recorded on the company's balance sheet. Investors also form their own opinion of Can Fite's value that differs from its market value or its book value, called intrinsic value, which is Can Fite's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Can Fite's market value can be influenced by many factors that don't directly affect Can Fite's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Can Fite's value and its price as these two are different measures arrived at by different means. Investors typically determine if Can Fite is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Can Fite's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.